Release Date: Thursday, October 16, 2014
Expiration Date: Thursday, October 15, 2015
Estimated Time To Complete Activity: 45 minutes
This CME-certified on-demand activity, developed by Axel Grothey, MD, is based on frequently asked questions posed during presentations conducted by expert faculty at the live grand rounds entitled, “Improving Overall Survival in mCRC: The Role of Sustained VEGF Inhibition,” at academic centers and medical institutions throughout the United States. This activity will allow participants to gain perspective on unanswered questions pertaining to the treatment of metastatic colorectal cancer, including anti-VEGF agents recently approved by the FDA and promising emerging agents in clinical trials, in an effort to help incorporate emerging evidence into clinical practice.
To access this activity, please click the ‘Download Activity' button above.
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above
For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
This activity has been designed to meet the educational needs of community and academic medical, surgical, and radiation oncologists; oncology nurses; and other professionals involved in the treatment of patients with mCRC.
At the conclusion of this activity, participants should be able to:
Use RAS mutation testing according to practice guidelines to manage treatment selection for patients with mCRC
Evaluate the role of maintenance therapy with antiangiogenic agents for patients with mCRC
Implement appropriate decision-making tactics for the treatment of mCRC with targeted agents in the first-line setting and beyond based on recent clinical data and current guidelines
Assess data from clinical trials evaluating the use of perioperative therapy in the resection of liver metastases
Determine the optimal dosing of currently approved oral agents for the treatment of mCRC
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Axel Grothey, MD, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., sanofi US; Contracted Research, Bayer Pharmaceuticals Corporation, Daiichi-Sankyo, Inc., Eisai Inc., Genentech, Inc., Morphotek, Inc.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS; Deborah Middleton, MS; and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.
To contact PIM, please visit www.pimed.com.
Internet: Web-Archive (Internet)
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Jointly provided by
Postgraduate Institute for Medicine and AXIS Medical Education, Inc.
This activity is supported by independent educational grants from Genentech, Sanofi US and Regeneron Pharmaceuticals, and Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.